- Weber B, Meldgaard P, Hager H, Wu L, Wei W,
Tsai J, Khalil A, Nexo E, Sorensen BS (2014)
Detection of EGFR mutations in plasma and
biopsies from non-small cell lung cancer
patients by allele-specific PCR assays. BMC
Cancer 14(1):294.https://doi.org/10.1186/
1471-2407-14-294. - Cross DA, Ashton SE, Ghiorghiu S,
Eberlein C, Nebhan CA, Spitzler PJ, Orme
JP, Finlay MR, Ward RA, Mellor MJ,
Hughes G, Rahi A, Jacobs VN, Red
Brewer M, Ichihara E, Sun J, Jin H, Ballard P,
Al-Kadhimi K, Rowlinson R, Klinowska T,
Richmond GH, Cantarini M, Kim DW, Ranson
MR, Pao W (2014) AZD9291, an irreversible
EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer.
Cancer Discov 4(9):1046–1061.https://doi.
org/10.1158/2159-8290.CD-14-0337 - Zhou W, Ercan D, Chen L, Yun CH, Li D,
Capelletti M, Cortot AB, Chirieac L, Iacob
RE, Padera R, Engen JR, Wong KK, Eck MJ,
Gray NS, J€anne PA (2009) Novel mutant-
selective EGFR kinase inhibitors against
EGFR T790M. Nature 462
(7276):1070–1074. https://doi.org/10.
1038/nature08622 - Oxnard GR, Thress KS, Alden RS, Lawrance R,
Paweletz CP, Cantarini M, Yang JC, Barrett
JC, J€anne PA (2016) Association between
plasma genotyping and outcomes of treatment
with osimertinib (AZD9291) in advanced
non–small-cell lung cancer. J Clin Oncol 34
(28):3375–3382. https://doi.org/10.1200/
JCO.2016.66.7162
54.http://www.fda.gov/ucm/groups/fdagov-
public/@fdagov-meddev-gen/documents/
document/ucm510824.pdf - Sequist LV, Yang JC, Yamamoto N,
O’Byrne K, Hirsh V, Mok T, Geater SL,
Orlov S, Tsai CM, Boyer M, Su WC,
Bennouna J, Kato T, Gorbunova V, Lee KH,
Shah R, Massey D, Zazulina V, Shahidi M,
Schuler M (2013) Phase III study of afatinib
or cisplatin plus pemetrexed in patients with
metastatic lung adenocarcinoma with EGFR
mutations. J Clin Oncol 31(27):3327–3334.
https://doi.org/10.1200/JCO.2012.44.
2806 - FDA http://www.accessdata.fda.gov/cdrh_
docs/pdf12/P120022c.pdf - Douillard J, Ostoros G, Cobo M, Ciuleanu T,
McCormack R, Webster A, Milenkova T
(2014) First-line gefitinib in Caucasian EGFR
mutation-positive NSCLC patients: a phase-
IV, open-label, single-arm study. Br J Cancer
110(1):55–62.https://doi.org/10.1038/bjc.
2013.721
58.http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_Product_Informa
tion/human/001016/WC500036358.pdf
59.http://www.fda.gov/Drugs/
InformationOnDrugs/ApprovedDrugs/
ucm504540.htm- Jenkins S, Yang J, Ramalingam S, Yu K, Patel S,
Weston S, Lawrance R, Cantarini M, J€anne P,
Mitsudomi T (2016) 134O_PR: plasma
ctDNA analysis for detection of EGFR
T790M mutation in patients (pts) with EGFR
mutation-positive advanced non-small cell lung
cancer (aNSCLC). J Thorac Oncol 11((4):
S153–S154. https://doi.org/10.1016/
S1556-0864(16)30327-6 - Lanman RB, Mortimer SA, Zill OA,
Sebisanovic D, Lopez R, Blau S, Collisson
EA, Divers SG, Hoon DS, Kopetz ES, Lee J,
Nikolinakos PG, Baca AM, Kermani BG,
Eltoukhy H, Talasaz A (2015) Analytical and
clinical validation of a digital sequencing panel
for quantitative, highly accurate evaluation of
cell-free circulating tumour DNA. PLoS One
10(10):e0140712.https://doi.org/10.1371/
journal.pone.0140712 - Zill OA, Mortimer S, Banks K (2016) Somatic
genomic landscape of over 15,000 patients
with advanced-stage cancer from clinical next-
generation sequencing analysis of circulating
tumour DNA. J Clin Oncol 34(suppl) - Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ,
J€anne PA, Costa DB, Varella-Garcia M, Kim
WH, Lynch TJ, Fidias P, Stubbs H, Engelman
JA, Sequist LV, Tan W, Gandhi L, Mino-
Kenudson M, Wei GC, Shreeve SM, Ratain
MJ, Settleman J, Christensen JG, Haber DA,
Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate
AJ (2010) Anaplastic lymphoma kinase inhibi-
tion in non–small-cell lung cancer. N Engl J
Med 363(18):1693–1703. https://doi.org/
10.1200/JCO.2016.34.15_suppl.LBA11501 - Koivunen JP, Kim J, Lee J, Rogers AM, Park
JO, Zhao X, Naoki K, Okamoto I,
Nakagawa K, Yeap BY, Meyerson M, Wong
KK, Richards WG, Sugarbaker DJ, Johnson
BE, J€anne PA (2008) Mutations in the LKB1
tumour suppressor are frequently detected in
tumours from Caucasian but not Asian lung
cancer patients. Br J Cancer 99(2):245–252.
https://doi.org/10.1038/sj.bjc.6604469 - Shaw AT, Yeap BY, Mino-Kenudson M, Digu-
marthy SR, Costa DB, Heist RS, Solomon B,
Stubbs H, Admane S, McDermott U,
Settleman J, Kobayashi S, Mark EJ, Rodig SJ,
Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ
(2009) Clinical features and outcome of
patients with non–small-cell lung cancer who
64 Jun Li et al.